Montreal, May 3, 2021 – Pendopharm is proud to launch SportVisTM, the first and only hyaluronic acid injection treatment that is clinically demonstrated and approved by Health Canada to relieve pain and restore function in damaged tendons and ligaments.
SportVisTM is a new, innovative soft tissue injury treatment that offers effective pain relief that gets you back to your activities fast.
“Pendopharm is proud to expand its Orthobiologics family of products with the addition of SportVis. The arrival of SportVis fills a major treatment gap for physicians in Canada. This innovative treatment is the first in its category and aims to treat tendon and ligament injuries which affects thousands of Canadians every year,” said Jad Isber, Vice President, and General Manager of Pendopharm.
Visit the website sportvis.ca to know more about this product.
Established in 2010, Pendopharm is the branded specialty division of Pharmascience Inc. We are a leading Canadian specialty pharmaceutical company dedicated to developing, in-licensing and commercializing innovative products. Pendopharm is committed to providing patients and the healthcare community with innovative medicines that address unmet medical needs. Our portfolio of branded products is focused on four core therapeutic areas, where we have proven expertise: Gastroenterology, Sports Medicine & Orthopedics, Neurology and Cardiology. In addition, we have a portfolio of established medicines, offering more than 40 specialty products across multiple therapeutic areas.
For product information, please contact Pharmascience’s Medical Information Department at 1-888-550-6060.
SPORTVISTM is a trademark of MDT Int’l. SA.